-
LabConnect Partners with The Bracken Group to Expand Radiopharmaceutical Support Services
JOHNSON CITY, Tenn., Sept. 23, 2025 -- LabConnect, a leading provider of global central laboratory and support services for clinical trials, announces a strategic collaboration with The Bracken Group to enhance its radiopharmaceutical support capabilities. As demand for radiopharmaceutical expertise continues to surge, with industry growth estimated between 15% and 20% annually, this collaboration positions LabConnect to better serve biotech and pharmaceutical clients advancing targeted treatments and diagnostics. The Bracken Group (Bracken) is widely recognized for its
- 김갑성 기자
- 2025-09-23 21:15
-
Kemin Industries Acquires CJ Bio Subsidiary CJ Youtell Biotech
Specializing in enzymes and fermentation, the biotech company will transform the expansion of Kemin's global enzyme production capabilities DES MOINES, Iowa and SHANGHAI, Sept. 23, 2025 -- Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services, is pleased to announce its acquisition of CJ Youtell Biotech, the enzymes and fermentation subsidiary of CJ Bio. This strategic move strengthens Kemin's position as a global leader in enzyme innovation for markets su
- 김갑성 기자
- 2025-09-23 21:00
-
Pictor Secures Funding to Accelerate U.S. Expansion through Partner-Informed Proteomics Solutions
CARLSBAD, Calif., Sept. 23, 2025 -- Pictor Holdings Inc., a global leader in targeted, multiplex proteomics, today announced the close of a convertible note funding round led by existing investors. The raise underscores strong confidence in Pictor's strategic expansion and recent establishment of its U.S. headquarters in Carlsbad, California. The convertible note funding represents a significant milestone in Pictor's growth trajectory and will serve as a bridge to the company's upcoming Series A funding round. Lead investor Marko Bogoievski commented, "I am proud to suppor
- 김갑성 기자
- 2025-09-23 21:00
-
Noul Secures FDA Registration for Cervical Cancer Diagnostic Cartridge
FDA registration fulfills requirements for U.S. market entry Initial shipments to Europe and Latin America to begin with pre-approved countries YONGIN, South Korea, Sept. 23, 2025 -- Noul Co., Ltd. (CEO: David Lim), a medical AI company specializing in blood and cancer diagnostics, announced that FDA registration has been completed for its cervical cancer diagnostic cartridge miLab™ Cartridge CER and clearing agent SafeFix™ CER, both core components of the company's cervical cancer diagnostic solution miLab™ CER. With this registration, Noul has fulfilled
- 김갑성 기자
- 2025-09-23 21:00
-
케민인더스트리즈, CJ Bio의 자회사 CJ유텔바이오텍 인수
효소 및 발효를 전문으로 하는 바이오테크 회사 인수로 케민의 전 세계 효소 생산능력이 획기적으로 증가할 전망이다 아이오와주 디모인 및 상하이, 2025년 9월 23일 -- 제품과 서비스를 통해 80%에 달하는 전 세계 소비자의 지속적인 삶의 질 혁신에 매진하는 세계적인 원료 제조업체 케민인더스트리즈(Kemin Industries)가 효소와 발효를 전문으로 하는 CJ Bio의 자회사 CJ유텔바이오텍(CJ Youtell Biotech)을 인수한다. 이 전략적 결정으로 케민은 동물 사료, 식품, 양식업, 섬유, 제지 및 펄프, 바이오 연료 산업 등의 시장에서 효소 혁신 분야 세계 선두 기업으로서 더욱 견고한 입지를 만들 전망이다. 이번 인수로 케민은 CJ유텔 발효 공장과 효소 제품 포트폴리오의 완전 소유권을 갖게 된다. CJ유텔은 전략적 차원에서 중국 산둥성과 후난성에 건립한 공장을 비롯해 세계 정상급 발효 플랫폼을 케민에 지원하게 된다. 새로운 인프라를 확보함에 따라 케민은 효소 사업을 확장해 환경친화적인 첨단 효소 기술로 생산한 원료를 전 세계 고객에게 직접 공급할 수 있게 됐다. 케민인더스트리즈의 사장이자
- 김갑성 기자
- 2025-09-23 21:00
-
HKeyBio Lauched the Most Comprehesive Non-human Primate Autoimmune & Allergic Disease Model Matrix to Redefining Clinical Translation
BOSTON and SUZHOU, China, Sept. 23, 2025 -- HKeyBio, a CRO specializing in preclinical and translational autoimmune-drug development, today announced the launch of HKEY-NHP-MATRIX2.0, a next-generation platform designed to improve the reliability of translating novel autoimmune and allergy therapies from preclinical research to clinical success. Platform Highlights Broad Primate Disease Model LibraryThe platform includes over twenty non-human primate (NHP) models spanning autoimmune and allergic diseases in four major categories: dermatology, respiratory, gastroenterology, an
- 김갑성 기자
- 2025-09-23 20:35
-
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON, Sept. 23, 2025 -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad's advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS' broad, decentralized network of more than 800
- 김갑성 기자
- 2025-09-23 20:01
-
女性の鉄欠乏症に生物学的イノベーションが効く - 今や3大陸で認知されている
STOCKHOLM, 2025年9月23日 -- 女性の鉄吸収を改善するよう設計された健康ソリューションが国際的な称賛を集め、欧州、北米、そしてアジアで最高賞を受賞しました。2025年におけるこの3つの認定は、より効果的で忍容性の高い鉄補給の必要性に対する世界的な意識の高まりを浮き彫りにしています。 バイオティクス・ソリューション企業のProbi社が開発した のコンセプトには、臨床研究済みのプロバイオティクス菌株、ラクリプランティバチルス・プランタルム 299v (LP299V®)が含まれています。鉄分と組み合わせると、LP299V®は鉄分の吸収を高め、従来のサプリメントに関連する消化器系の副作用を軽減します。 鉄分不足は世界中で最も差し迫った栄養的課題の一つであり、女性の30%以上が影響を受けています。単に鉄分を追加するのではなく、Probiの特許技術を持つ菌株は、体がより効果的に鉄分を吸収できるようにサポートします。LP299V®は2つの重要な方法で鉄の取り込みをサポートする：鉄分を吸収可能な形で保持し、鉄を変換する酵素の体内での発現を増加させることによって。これにより、食品やサプリメントからの吸収が改善されます。 「1年間で3大陸からの認識は、この問題の緊急性と、科学に裏
- 김갑성 기자
- 2025-09-23 18:58
-
Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
CHENGDU, China, Sept. 23, 2025 -- The 2025 European Society for Medical Oncology (ESMO) Congress will take place in Berlin, Germany, from October 17 to 21. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) will present results from multiple clinical studies at the congress, including data from its TROP2 ADC sacituzumab tirumotecan (sac-TMT), HER2 ADC A166 (trastuzumab botidotin), and CLDN18.2 ADC SKB315. Among these, two Phase III clinical studies of sac-TMT were selected for the Latest Breakthrough Abstracts (LBA) and presented as oral reports,
- 김갑성 기자
- 2025-09-23 17:03
-
Economist Impact's 5th edition Future of Health Asia returns to Singapore amid rising technological disruption, chronic disease burdens and international trade tensions
Singapore to host 500 health, science and policy leaders on October 16th to address pressing issues in the Asia-Pacific healthcare sector. Members of the media are invited to register here. SINGAPORE, Sept. 23, 2025 -- Convening on October 16th at the Four Seasons Hotel, the 5th edition Future of Health Asia will bring together 500 senior leaders from healthcare, government and patient advocacy to examine the impact of rising technological disruptions, rising pressure of chronic diseases and global economic uncertainty. The Asia-Pacific's healthcare secto
- 김갑성 기자
- 2025-09-23 14:50
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-11-04_TUE
- The New SkyReels Officially Launches 23:50
- China opens door wider to share more opportunities with world 23:43
- ARDY FERGUSONが名誉あるS.PELLEGRINO YOUNG CHEF ACADEMY AWARD 2025を受賞 23:24
- Visionary Holdings Inc. Announces Successful Leadership Transition: Elite Governance Team Leads the Way, Standardized Structure Empowers High-Quality Development 22:30
- IMG Announces Winner of First Student Journey Scholarship 22:00
- Metabolon Powers Largest-Ever Veteran Metabolomics Study with Global Discovery Panel 22:00
- NYSE Content Advisory: Pre-Market Update + BETA Technologies Raises Over $1 Billion in IPO 21:59
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 11월 05일 01시 20분